Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab consolidation after chemoradiotherapy for limited-stage small cell lung cancer
NL-OMON45134Phase 2Active, not recruiting
- Sponsor
- European Thoracic Oncology Platform
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in small cell lung cancer (SCLC) (2 arms), sponsored by European Thoracic Oncology Platform. Primary endpoints: Progression-free survival and Overall survival. Started Nov 2015; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON45134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45134.